Targeting amyloid proteins for clinical diagnosis of neurodegenerative diseases
Open Access
- 1 July 2023
- journal article
- review article
- Published by KEAI Publishing in Fundamental Research
- Vol. 3 (4) , 505-519
Abstract
Abnormal aggregation and accumulation of pathological amyloid proteins such as amyloid-β, Tau, and α-synuclein play key pathological roles and serve as histological hallmarks in different neurodegenerative diseases (NDs) such as Alzheimer's disease (AD) and Parkinson's disease (PD). In addition, various post-translational modifications (PTMs) have been identified on pathological amyloid proteins and are subjected to change during disease progression. Given the central role of amyloid proteins in NDs, tremendous efforts have been made to develop amyloid-targeting strategies for clinical diagnosis and molecular classification of NDs. In this review, we summarize two major strategies for targeting amyloid aggregates, with a focus on the trials in AD diagnosis. The first strategy is a positron emission tomography (PET) scan of protein aggregation in the brain. We mainly focus on introducing the development of small-molecule PET tracers for specifically recognizing pathological amyloid fibrils. The second strategy is the detection of PTM biomarkers on amyloid proteins in cerebrospinal fluid and plasma. We discuss the pathological roles of different PTMs in diseases and how we can use the PTM profile of amyloid proteins for clinical diagnosis. Finally, we point out the potential technical challenges of these two strategies, and outline other potential strategies, as well as a combination of multiple strategies, for molecular diagnosis of NDs.Keywords
Funding Information
- National Natural Science Foundation of China (31872716, 32170683, 32171236, 82188101)
- Science and Technology Commission of Shanghai Municipality (2019SHZDZX02, 20XD1425000)
- Chinese Academy of Sciences, Shanghai Branch (CYJ-SHFY-2022-005)
This publication has 187 references indexed in Scilit:
- The Amyloid State of Proteins in Human DiseasesCell, 2012
- Tau and Tauopathies2012
- Soluble Aβ oligomer production and toxicityJournal of Neurochemistry, 2011
- Amyloid Precursor Protein Processing and Alzheimer's DiseaseAnnual Review of Neuroscience, 2011
- The Amyloid–Congo Red Interface at Atomic ResolutionAngewandte Chemie International Edition, 2011
- Protein-induced photophysical changes to the amyloid indicator dye thioflavin TProceedings of the National Academy of Sciences of the United States of America, 2010
- Molecular mechanisms of neurodegeneration in Alzheimer's diseaseHuman Molecular Genetics, 2010
- Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjectsAnnals of Neurology, 2009
- Phosphorylated TDP‐43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosisAnnals of Neurology, 2008
- Protein aggregation and neurodegenerative diseaseNature Medicine, 2004